Patent · US Expired

Lymphocyte function antigen-1 antagonists

US6630492B1 · kind B1 · utility

13Cited by

9References

11Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Wilfried Bauer · Lampenberg, CH
Sylvain Cottens · Witterswil, CH
Dieter Geyl · Heitersheim, DE
Gabriele Weitz-Schmidt · Bad Krozingen, DE
Jörg Kallen · Basel, CH
Ulrich Hommel · Mülheim, DE

Key dates

Filing date	Feb 24, 2000
Grant date	Oct 7, 2003
Priority date	—
Expiry date	Feb 24, 2020

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2602/28
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Mevinolin compounds for use in the treatment or prevention of autoimmune diseases, inflammation, ischemia/reperfusion injury and graft rejection. Such compounds bind to the LFA-1 I-domain and thereby inhibit LFA-1/ICAM-1 or LFA-1/ICAM-3 interactions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.